Prevail Therapeutics — Q2 2020 Earnings Presentation
21 slides from Prevail Therapeutics's earnings presentation, Aug 11, 2020
Slide 1: Second Quarter Clinical and Financial Update
Second Quarter Clinical and Financial Update August 11, 2020
Slide 2: Forward-looking statements disclaimer
Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to
Slide 3: Call agenda
Introduction Brett Kaplan, M.D., Chief Financial Officer Overview Asa Abeliovich, M.D., Ph.D., CEO & Founder Clinical Update Jeffrey Sevigny, M.D., Chief Medical Officer Financial Update Brett Kaplan, M.D., Chief Financial Officer Q&A Call agenda
Slide 4: Overview
Overview Asa Abeliovich, M.D., Ph.D., CEO & Founder
Slide 5: Focused on our mission
Focused on our mission Phase 1/2 PROPEL trial for Parkinson’s with GBA1 mutations (PD-GBA) underway; PD-GBA affects >90K Americans Potential for rapid proof-of-concept for PR001 in neuronopathic Gaucher disease; PROVIDE trial planned to initiate enrollment in 2H 2020 Large Market & Near-Term Value I
Slide 6: Rapid advancement to clinical stage
2017 2018 2019 2020 Rapid advancement to clinical stage OCTOBER 2017: Lab space secured in NYC AUGUST 2017: Seed financing and REGENXBIO license MAY 2018: REGENXBIO second agreement MARCH 2018: $75M Series A MAY 2019: PR001 PD-GBA IND active MARCH 2019: $50M Series B JUNE 2019: $125M IPO DECEMBER 20
Slide 7: Unique pipeline of potentially disease-modifying AAV9 gene therapies
Unique pipeline of potentially disease-modifying AAV9 gene therapies for neurodegenerative diseases Programs Indication Approach Stage of Development Discovery Preclinical Phase 1/2 Pivotal PR001 PD-GBA GBA1 Gene Transfer Neuronopathic Gaucher disease GBA1 Gene Transfer PR006 FTD-GRN GRN Gene Transf
Slide 8: Second quarter business highlights
Clinical development of PR001 advances Two nGD patients dosed via compassionate use requests Two PD-GBA patients enrolled in Phase 1/2 PROPEL trial Encouraging early data available from one nGD patient and one PD-GBA patient In both patients CSF GCase levels were undetectable at baseline; normalized
Slide 9: Clinical Update
Clinical Update Jeffrey Sevigny, M.D., Chief Medical Officer
Slide 10: PR001 program update
PR001 program update PROVIDE Phase 1/2 trial for Type 2 Gaucher disease anticipated to initiate enrollment in 2H 2020 Two patients enrolled in PROPEL Phase 1/2 trial for PD-GBA One patient received 1.4x1014 vg of PR001; second patient received sham procedure PROPEL enrollment expected to continue in
Slide 11: Type 2 Gaucher compassionate use: early patient data
Type 2 Gaucher disease patient dosed with PR001 (1.3x1014 vg) in Jan 2020 following compassionate use request Patient was ~22 months old at dosing CSF GCase enzyme activity increased from undetectable at baseline to normal level at Month 4 Type 2 Gaucher compassionate use: early patient data PR001 I
Slide 12: PROPEL PD-GBA Phase 1/2 trial: early patient data
Two PD-GBA patients enrolled in PROPEL trial: one administered PR001; one received sham procedure Patient who received PR001 (1.4x1014 vg) also diagnosed with Gaucher disease (GBA1 mutations in both chromosomal copies) CSF GCase enzyme activity increased from undetectable at baseline to normal level
Slide 13: PROPEL PD-GBA Phase 1/2 trial updates
PROPEL PD-GBA Phase 1/2 trial updates Protocol amendment endorsed by IDMC, discussed with and submitted to FDA Patient enrollment expected to continue in 2H 2020 Next biomarker and safety analysis on subset of patients by mid-2021 ü ü ü Amendment implemented to mitigate risk of AAV9-mediated immune
Slide 14: Revised PR001 PD-GBA Phase 1/2 trial
Revised PR001 PD-GBA Phase 1/2 trial Open label, ascending dose PR001 Low Dose (N=6) PR001 High Dose (N=6) Single or biallelic GBA1 mutations Moderate to severe Parkinson’s disease Stable background PD medication Safety and tolerability Key biomarkers: GCase, GluCer, GluSph (CSF and blood) Additiona
Slide 15: Goal of PR001 treatment is to restore GCase activity
Goal of PR001 treatment is to deliver the GBA1 gene to restore GCase activity in PD-GBA patients Source: Liu et al., Annals of Neurology 2016; Thaler et al., Parkinsonism and Related Disorders 2017 Pre-PR001 Treatment Goal of PR001 Treatment PR001 ~50% of healthy GCase PD-GBA ~75% of healthy GCase U
Slide 16: PR001 Type 2 Gaucher disease Phase 1/2 trial
ICM: intra-cisterna magna; QoL: quality of life; SoC: standard of care; PEG: percutaneous endoscopic gastrostomy PR001 (Open label, N=15) Infants 0-24 months old Biallelic GBA1 mutations Neurological signs & symptoms consistent with Type 2 Gaucher disease Stable SoC background medications Safety and
Slide 17: PR006 FTD-GRN Phase 1/2 trial
ICM: intra-cisterna magna; NfL: neurofilament light chain; CDR plus NACC FTLD: Clinical Dementia Rating plus National Alzheimer’s Coordinating Center Frontal Temporal Lobar Dementia; QoL: quality of life PR006 Mid Dose (N=5) 30-80 years old Single pathogenic GRN mutation Symptomatic disease stage St
Slide 18: Financial Update
Financial Update Brett Kaplan, M.D., Chief Financial Officer
Slide 19: Second quarter 2020 financial update
Second quarter 2020 financial update Cash (inclusive investment purchases) of $131.2 million as of June 30, 2020, as compared to $149.6 million as of March 31, 2020 Cash runway remains into first half of 2022 Cash Position R&D Expenses G&A Expenses $12.9 million for second quarter of 2020, compared
Slide 20: Prevail
Preyuil
Slide 21: Therapeutics
THERAPEUTICS.